Bioherent
Alhaurín De La Torre
About Bioherent
Bioherent develops in vitro diagnostic systems for the detection of allergies to beta-lactam antibiotics. Bioherent is based on integrated photonic sensors, and the company provides medical diagnostic tests for the detection of drug allergies. It develops sensitive, low-cost, in-vitro medical diagnostic technology. They develop in vitro diagnostic systems for the detection of allergies to beta-lactam antibiotics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $1.5M
- Funding stage: Seed
- Last round: Seed (Jul 2025)
- Website: bioherent.com
Industries & Categories
Biotechnology, Health Diagnostics, Manufacturing, Medical, Test and Measurement
Social Profiles
Canonical: https://fsome.com/organization/bioherent-28027 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.